Dirk Grimm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Better Outfitted and Screened Viral Vectors Are Safer and More Effective Better Outfitted and Screened Viral Vectors Are Safer and More Effective Adeno-associated virus (AAV) vectors are the leading vectors for gene delivery. Two AAV-based gene therapies have been approved by the U.S. Food and Drug administration, and dozens more are in clinical trials. However, AAV vectors pose challenges including costly manufacture, high percentages of empty capsids, and safety issues associated with high-dose regimens. To address this last challenge, developers are working to improve the impact of each A...

Sanofi partners with SIRION to improve AAV capsids for gene therapy treatments 24th February 2021 SIRION Biotech has signed a license and collaboration with Sanofi to develop improved adeno-associated virus capsids for gene therapy treatments for disorders affecting major human organs. Sanofi, working with SIRION Biotech and professor Dirk Grimm, a scientist in the field of AAV biology and application working at Heidelberg University Hospital in Germany, will combine their technology platforms to create next-generation AAV vectors. As part of the collaboration, the partners will aim to develo...

(Sanofi) French Big Pharma Sanofi is teaming up with Germany’s Sirion Biotech for its viral-vector-based gene delivery tech. The pair will work together on developing improved tissue-selective adeno-associated virus (AAV) vectors to tee up better gene therapy treatments. Targets have not yet been specifically mentioned, simply for “disorders affecting major human organs.” Financials of the deal were not made public. This comes two years after Sirion penned a similar pact with Denali Therapeutics, with other partners including Acucela and Orchard Therapeutics. Sanofi will work w...

Posted on 192 SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs. AAV vectors are a promising and clinically validated gene delivery platform for the potential treatment of a variety of human diseas...

(2) Joining forces to develop gene therapies for multiple life-threatening disorders SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs. AAV vectors are a promising and clinically validated gene delivery platform for the potential treatment of a variety of h...